- Report
- August 2023
- 235 Pages
Global
From €4780EUR$5,132USD£3,950GBP
- Report
- February 2024
- 115 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- October 2023
- 170 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Report
- February 2022
- 199 Pages
Global
From €5062EUR$5,250USD£4,329GBP
- Report
- July 2022
- 600 Pages
Global
From €3182EUR$3,300USD£2,721GBP
- Report
- October 2019
- 170 Pages
Global
From €2507EUR$2,600USD£2,144GBP
- Report
- December 2022
- 150 Pages
Global
From €5736EUR$5,950USD£4,906GBP
- Report
- April 2023
- 500 Pages
Global
From €3615EUR$3,750USD£3,092GBP
- Report
- April 2020
- 150 Pages
Global
From €6701EUR$6,950USD£5,731GBP
- Report
- April 2022
Global
€7713EUR$8,000USD£6,596GBP
- Report
- October 2018
- 386 Pages
Global
From €3905EUR$4,050USD£3,339GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2892EUR$3,000USD£2,474GBP
- Report
- November 2021
- 1165 Pages
Global
From €5785EUR$6,000USD£4,947GBP
- Report
- July 2023
- 140 Pages
Global
From €5784EUR$5,999USD£4,946GBP
The Personalized Cancer Vaccine market is a subset of the Genomics market, focused on the development of vaccines tailored to an individual's genetic makeup. This approach to cancer treatment is based on the idea that each person's cancer is unique, and that a vaccine tailored to their specific genetic profile can be more effective than a generic vaccine. The personalized cancer vaccine market is driven by advances in genomics technology, which allow for the rapid sequencing of an individual's genome and the development of a vaccine tailored to their specific genetic profile.
The personalized cancer vaccine market is expected to grow in the coming years, as more research is conducted and more personalized vaccines are developed. Companies in the market include Adaptive Biotechnologies, Immunovant, and Oncolytics Biotech. Show Less Read more
